This 6-K is a scheduling notice with no standalone trading signal. The event to watch is the August 20, 2026 Q2 results/business update, for a clinical-stage company with a roughly $27M market cap, the focus will be on cash position, runway, and any pipeline catalysts. Avoid pre-positioning based on this notice alone.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $3.34entry
- T+1 · 3mo ago −6.29%α −5.81% · $3.13
- T+5 · 3mo ago −0.90%α +0.47% · $3.31
- T+20 · 2mo ago −8.08%α −6.09% · $3.07
- T+60 · 8d ago −17.66%α −14.62% · $2.75
Price Chart
How similar events traded
Executive Summary
Evaxion A/S filed a Form 6-K on August 14, 2026, announcing that it will release a business update and Q2 2026 financial results on August 20, 2026, before the Nasdaq CM open, followed by a conference call and webcast. This is a routine earnings-date notification with no financial figures or new clinical data disclosed.
Key Facts
- Evaxion will report Q2 2026 financial results and provide a business update on August 20, 2026, before market open.
- Executive management will host a conference call and webcast on August 20, 2026 at 14:30 CET / 08:30 EST.
- Press release dated August 14, 2026 was furnished as Exhibit 99.1 to the 6-K.
- No financial figures, guidance, or clinical pipeline updates were included in this filing.
Financial Impact
No financial figures disclosed in this filing, the announcement only schedules the Q2 2026 results and business update for August 20, 2026.
Risk Factors
- No financial data provided, elevated binary event risk at the August 20 earnings release.
- Clinical-stage TechBio profile implies potential need for additional capital, which may dominate the upcoming update.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005527 |
| Exhibit: exh_991.htm | 0001171843-26-005527 |
| Document: 0001171843-26-005527-index-headers.html | 0001171843-26-005527 |
| Document: 0001171843-26-005527-index.html | 0001171843-26-005527 |
| Document: 0001171843-26-005527.txt | 0001171843-26-005527 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers